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Radionuclide synovectomy/synoviorthesis (RS) in persons with 
bleeding disorders: A review of impact of national guidance on 
frequency of RS using the ATHNdataset
Radionuclide synovectomy/synoviorthesis (RS) is a procedure in 
which radio- active pharmaceuticals are injected into the joint space 
of someone affected by a proliferative synovial disorder to de-
crease synovitis. Radiation is delivered to the synovium with mini-
mal penetration to deeper joint structures. Historically, this was a 
fairly common procedure for persons with haemophilia and other 
bleeding disorders because it can be performed in an outpatient 
setting with relatively minimal clotting factor concentrate replace-
ment.1 Numerous patients with bleeding disorders have had RS 
with various isotopes, since this procedure was first described in 
1963 with Phosphocol P32 (chromic phosphate P32 suspension), 
the most commonly utilized isotope in the US.1-8 However, pa-
tient safety concerns arose after two reports of acute leukaemia 
in children with haemophilia within 1 year of RS were published 
in 2002 and 2005,9,10 which prompted the medical and scientific 
advisory council (MASAC) to the National Hemophilia Foundation 
to issue recommendation # 176 on 15th October 2006.11 This 
recommendation suggested careful consideration of the risk ben-
efit ratio of RS and utilization of a standardized RS protocol. On 
18th September 2008 the Food and Drug Administration (FDA) 
issued a MedWatch regarding the use of P32 for intra- articular 
use indicating that P32 may increase the risk for leukaemia in cer-
tain situations and stating that it was not indicated in the intra- 
articular treatment of hemarthrosis.12 Subsequently in 2012 a large 
Canadian retrospective cohort study of cancer incidence after RS 
did not identify a correlation between RS and cancer.13 Finally, 
the first case of solid tumour- Ewing sarcoma diagnosed after RS 
was published in 2013.8 With conflicting publications/recommen-
dations about this procedure, we hypothesized that the American 
Thrombosis and Hemostasis Network (ATHN) ATHNdataset, which 
includes US individuals with bleeding disorders who are cared for in 
Health Resources and Services Administration (HRSA) haemophilia 
regions (Figure 1) and have authorized the sharing of their demo-
graphical and clinical information for research would allow inter-
rogation of rates of RS utilization related to selected publications/
guidance documents.
American Thrombosis and Hemostasis Network 3 is a working 
group of adult and paediatric haematologists and ATHN support 
staff with interest in RS. The ATHN3 working group designed and 
performed a retrospective multi- institution, observational cohort 
study utilizing the data set that included any patient with a bleeding 
disorder who had undergone a RS procedure through 31/12/2014. 
The ATHNdataset includes data contributed from 135 HTC’s from 
eight regions. A standard data collection template was utilized by 
participating Hemophilia Treatment Centers (HTC’s) to validate 
RS patient data in the ATHNdataset. The chi- square test was uti-
lized to verify the hypothesis. The prevalence of RS in relation to 
six publications/guidance documents that were determined by the 
ATHN3 working group was considered. These included publications 
regarding: two cases of leukaemia the first in 2002 and the sec-
ond in 2005, the MASAC guideline on RS #176 in 2006, FDA P32 
MedWatch warning regarding P32 in 2008, a comprehensive safety 
review of Canadian P32 cases in 2012 and a case of Ewing sarcoma 
in 2013.
As of 31/12/2014, the ATHN data set included a total of 19,735 
bleeding disorder patients. Of the 135 HTCs contributing data to the 
ATHNdataset, 38 had reported 362 RS procedures in 196 patients. 
Age at RS ranged from 4 to 72 years (median 15 years). Ninety- five 
per cent of patients who had RS had haemophilia A or B and 97% 
were male. Overall, the proportions of patients of different races and 
ethnicity who had RS did not differ from data set participants who did 
not have RS.
The mean annual number of procedures increased between leu-
kaemia case #1 and leukaemia case #2 from 18 to 21 (Figure 2). The 
mean number of annual procedures decreased slightly after MASAC 
guidance in 2006 and has continued to decline thereafter. Mean RS in-
stillations decreased from 13 per year before the MedWatch warning 
in 2008 to 12 in 2012, and to 7 by 31/12/2014. A total of 149 (43%) 
of injections were performed between the first leukaemia report and 
the Canadian safety report in 2012. The annualized number of RS in-
jections performed after the Canadian safety report in 2012 was 7 
and the total number of RS procedures continued to decline after the 
Ewing sarcoma publication in 2013 to 3 in the year 2014.
There were significantly fewer patients who had repeated RS after 
the MASAC guidelines (17% vs. 83%; P<.001).We did not find race or 
ethnicity related differences in RS rates after the first publication of 
MASAC in 2006. About 27% of Caucasian and 25% of Non- Caucasian 
patients had RS after the MASAC guidelines (P=.821). The percentage 
of procedures performed in Hispanic or non- Hispanic patients after 
MASAC guidelines did not differ too much, 32% vs. 25% (P=.480). 
MASAC guidance did appear to impact the use of RS in some regions 
but not others (P<.001). After the MASAC guidelines the number 
of RS procedures dropped substantially for New England (from 31 
to 3), Great Lakes (from 90 to 16), Mountain States (from 16 to 2), 
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Great Plains (from 19 to 6) and the Southeast (from 80 to 38) regions. 
Northern States (from 8 to 6) and Western States (from 17 to 14) did 
not see the substantial reduction in the amount of RS procedures as 
the other regions. Interestingly enough, there was no significant differ-
ence between number of RS procedures performed in patients with in-
hibitors (32.8%) compared to patients without inhibitors (29.5%) after 
MASAC guidelines (P=.658).
Our study was limited by its retrospective database design. 
Practice changes such as increasing use of primary and secondary 
prophylaxis with resultant decrease in arthropathy as well as difficulty 
in obtaining P32 after the MedWatch warning may have influenced 
RS rates and could not be independently evaluated. A potential study 
of the rates of surgical synovectomies over this period may help dis-
cern these variables. In our study, we were unable to evaluate this 
because some patients who underwent RS also had surgical synovec-
tomies, and these variables were not mutually exclusive. Additionally, 
the short supply of P32 may have been a confounder of the impact 
of MASAC guidelines on the regional change in procedure as well.
The data suggests that the MASAC guidelines may influence gen-
eral practice. Another interesting observation was that the MASAC 
guidelines seem to be more impactful in certain regions as opposed to 
others. Regional differences may have been descriptive of individual 
preferences of groups of practitioners or institutions driven by factors 
including availability of someone to handle the radioactive isotope 
which is highly regulated, limited availability of experts to administer 
the injections and size of centres and patient volumes justifying pur-
chase of the isotope. Additionally, the ATHNdataset was utilized as a 
high quality data set in this study which paves the way for future stud-
ies using the ATHNdataset that may require evaluating a large popula-
tion of patients with bleeding disorders in multiple centres.
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